Prognostic value of EGFR mutation and ERCC1 in patients with non-small cell lung cancer undergoing platinum-based chemotherapy.

Prognostic value of EGFR mutation and ERCC1 in patients with non-small cell lung cancer undergoing platinum-based chemotherapy.

BACKGROUND: In order to improve the outcome of patients with non-small cell lung cancer (NSCLC), a biomarker that can predict the efficacy of chemotherapy is needed. The aim of this study was to assess the role of EGFR mutations and ERCC1 in predicting the efficacy of platinum-based chemotherapy and...

Full description

Bibliographic Details
Main Authors: Fumie Yamashita, Koichi Azuma, Tsukasa Yoshida, Kazuhiko Yamada, Akihiko Kawahara, Satoshi Hattori, Hiroaki Takeoka, Yoshiaki Zaizen, Tomotaka Kawayama, Masayoshi Kage, Tomoaki Hoshino
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3734014?pdf=render

Internet

http://europepmc.org/articles/PMC3734014?pdf=render

Similar Items